Many pathogens, including Streptococcus pneumoniae, are carried asymptomatically on the nasopharyngeal mucosa and spread among individuals by close contact. Clinical disease results when pneumococci escape from the mucosa and invade sterile sites. Although systemic immunity can prevent invasive disease, control of person-to-person spread is probably dependent on immunity acting at the mucosal surface. Intranasal immunization of mice with PspA (pneumococcal surface protein A) or a capsular 6B polysaccharide -tetanus toxoid conjugate induced mucosal and systemic antibody responses and provided long-lasting protection against carriage of S. pneumoniae. Resistance to carriage was dependent on mucosal rather than systemic immunity and was effective against heterologous strains of heterologous PspA types. Intranasal immunization with PspA also protected against systemic infection following intravenous, intratracheal, and intraperitoneal challenge.
The majority of infectious diseases directly affect or are mococci. Polysaccharide (PS) is antiphagocytic and is the most conspicuous protection-eliciting antigen of pneumococci. The acquired through the mucosal surfaces. For many organisms, colonization of the respiratory, gastrointestinal, and urogenital ability of serum antibodies to CPS to provide serotype-specific protection is well established [9] . Since children õ2 years of tracts is the first step in pathogenesis, and prevention of colonization should effectively block both transmission and infection.
age respond poorly to immunization with PS vaccines [10] , protein conjugates of PS are being investigated as a potential Specific immune protection of mucosal surfaces is mediated by the mucosal immune system and by the small amounts of human vaccine for children [11] . There are §90 different CPSs constituting 48 non -cross-reactive PS groups [12] . Thus, to serum immunoglobulin that reach these sites. The most conspicuous product of the mucosal immune system is secretory be effective, PS vaccines must contain multiple PS [13] . Pneumococci are acquired through aerosols or by direct conIgA. Generation of specific secretory IgA antibodies usually requires stimulation of specialized inductive sites of the mucotact and first colonize the upper airways, where they can be carried for weeks or months. Some 10% -20% of adults carry sal immune system. Only in recent years have effective strategies for immunization at these sites been developed [1] , and pneumococci in the upper nasopharynx at any time; colonization rates in young children and in the elderly are much higher. the development of mucosal vaccines has lagged behind conventional parenteral vaccination [2] .
In most cases, colonization does not result in apparent disease [14, 15] and even highly virulent strains can colonize without Streptococcus pneumoniae cause pneumonia, meningitis, otitis media, ocular infections, bacteremia, and sinusitis in hucausing disease [16, 17] . PspA is necessary for full virulence of pneumococci and mans and are a major cause of fatal infections worldwide [3 -5] . Capsular polysaccharide (CPS) [6, 7] and pneumococcal retards their clearance from the blood of mice [8, 18] . Antibody to PspA facilitates clearance and protects against death [8, 19 , surface protein A (PspA) [8] are both virulence factors in pneu-20]. Like CPS, PspA is variable in structure. PspA from different isolates usually differ in molecular weight, the combination of epitopes expressed [21 -23] , and pspA-associated restriction as the material from strain R36A [32] . This mock immunization
Since pneumococci colonize the nasopharynx and infect the always gave results identical to those obtained with CTB alone lungs and upper airway, we investigated the ability of mucosal (data not shown). 6B-TT was prepared by the method of Schneerimmunizations to block infection and colonization at these son et al. [36] and contained 3 mg of TT per 2 mg of 6B-PS. Mice sites. When pneumococci spread from the nasopharynx to the were bled 10 days after their last immunization. Saliva (Ç100 mL) lung, they must pass through bronchial tissue. Thus, mucosal was collected from mice 10 days after the last immunization by immunity at both the nasopharynx and bronchial sites might injection ip of 3-5 mg of carbachol to stimulate salivation using play a significant role in preventing pulmonary infection. We a pipette fitted with a plastic tip [37] . Antibody levels were deterimmunized mice intranasally (inl) with isolated PspA [32] to mined by ELISA using plates coated with isolated PspA or 6B-evaluate its ability to block inl or intratracheally (int) acquired PS. PS-specific antibody assays were done in the presence of pneumococcal CPS to prevent the detection of any antibody to cell infections. To test the ability of immunity to PspA to act at wall CPS [38] . Isotype specific antibody levels were determined by the mucosal surface, we also examined the ability of inl adminusing alkaline phosphatase-or peroxidase-conjugated antibodies istered PspA to elicit protection against nasal carriage of S.
specific for mouse immunoglobulin isotypes [37, 38] .
pneumoniae. Immunizations inl used the B subunit of cholera
Mouse challenge. Mice were challenged inl 2 weeks or 144 toxin (CTB) as adjuvant. CTBs greatly augment immune redays after the last immunization. Other mice were challenged int, sponses to protein antigens given inl [33] .
intravenously (iv), or ip 4 weeks after the last injection. Challenges ip and iv were done as previously described using log-phase pneumococci diluted in Ringer's lactate to the indicated number of
Methods
colony-forming units (cfu) [32] . Inoculation inl delivered 10 mL of Ringer's solution containing cfu into the nares of nonanestheMice. Mice used in these studies were 6-12 weeks old. BALB/ tized mice. We did inoculation int by a nonsurgical procedure that c mice were raised at the University of Alabama at Birmingham used a 69-mm finely drawn gel-loading plastic pipette tip (05-from BALB/cJ parents obtained from Jackson Laboratories (Bar 541-9; Fisher Scientific, Pittsburgh). Mice were anesthetized with Harbor, ME). CBA/CAHN-XID/J (CBA/N) mice were purchased ketamine and xylazine and placed on their backs with heads bent from Jackson Laboratories.
slightly back. Slight tension was applied to the tongue to expose Bacterial strains. Table 1 lists S. pneumoniae strains that we the glottis. The gel-loading tip was inserted into the glottis, and used for mouse challenge [34] . The only other strain used was 20 mL of bacteria in Ringer's injection solution was discharged R36A, an avirulent rough variant of capsular type 2 strain D39 [8, into the trachea. The course of infection and colonization was 35], which has been used for isolation of PspA.
followed by monitoring the numbers of cfu in the blood, homogeImmunizations, antigens, and ELISAs. Mice received three imnized lung, and nasal washes at various times after challenge. munizations inl 10 days apart. On each occasion, 150 ng of PspA
Bacteria from blood and lungs were plated in serial dilutions on or 1500 ng of a conjugate of 6B-PS with tetanus toxoid (6B-TT) blood agar plates so that cfu could be counted [20] . in 10-12 mL of Ringer's lactate was slowly delivered into the Nasal wash samples were collected from mice after sacrifice. nares. CTB (4-5 mg; List Biological Laboratories, Campbell, CA)
The trachea was cut at the top of the larynx, and 50 mL of Ringer's was included in the first two immunizations. Other mice received solution was injected and collected from the tip of the nose. The two systemic injections of 1 mg of PspA: The first was given bacteria were plated on blood-agar plates containing 4 mg/mL subcutaneously with complete Freund's adjuvant (CFA); the secgentamicin to inhibit the growth of most nonpneumococcal bacteond (20 days later) was given intraperitoneally (ip) without adjuria that might be present [39] . To further ensure that the bacteria vant. PspA for immunization was isolated from R36A pneumoobserved were pneumococci, samples were also plated on a second cocci on choline-Sepharose columns as described previously [32] .
set of gentamicin-containing plates that also contained 5 mg/mL For some control immunizations, we followed the same isolation procedure using strain WG44.1, which contains a mutation that optochin (ethyl hydrocupreine hydrochloride; Sigma, St. Louis).
/ 9d21$$ap14 02-21-97 18:06:43 jinfa UC: J Infect Immunization of CBA/N mice using similar intranasal and parStatistical analysis. We expressed antibody levels as geometenteral protocols elicited essentially the same responses (data ric means with the SE factor (the number by which a number must not shown) as obtained with BALB/c mice.
be multiplied or divided to obtain the upper or lower SE limits).
Protection against invasive disease by immunization inl with
Statistical differences were calculated with a one-tailed Wilcoxon two-sample rank test. P § .05 was considered nonsignificant.
PspA. To test the ability of immunization inl with PspA to protect against pulmonary infection, Ç100 LD 50 of A66 pneumococci were inoculated intratracheally (int) into BALB/c mice Results in 20 mL of Ringer's solution. Protection against acquisition Immune response to immunization inl with PspA. When inl of pneumococcal infection was tested by inoculating immugiven inl with CTB, 150-ng doses of PspA elicited significant nized CBA/N mice inl with 3 1 10 6 cfu of virulent A66 pneuIgA antibodies in saliva of BALB/cJ mice (table 2) . No IgG mococci. CBA/N, rather than BALB/c mice were used for antibody to PspA was detectable (õ0.01 mg/mL) after immunichallenge inl, because inoculation inl of A66 readily kills CBA/ N mice but does not kill 100% of BALB/c mice, even when zation inl. No antibody response to PspA was observed in the 8 cfu are inoculated. Immunization inl with PspA provided otherwise fatal challenge iv with S. pneumoniae A66 capsular type 3 ( figure 1C ). good protection against challenge both inl and int ( figure 1A,  B) . Challenge of mice int 144 days after immunization inl Although inoculation ip is not a natural route of pneumococcal infection, it has been widely used as a model for passive elicited long-term immunity ( figure 1A) .
Mice immunized inl with PspA and CTB were also protected immunity. Fewer pneumococci are needed to kill mice ip than by other challenge routes [40] . Previous studies have shown against sepsis and bacteremia; 3 days after challenge int, immune mice had õ30 cfu/mL in blood, whereas CTB control that subcutaneous immunization of mice with PspA can protect against death following challenge ip with S. pneumoniae [32] . mice had 10 4 -10 8 cfu/mL (data not shown). Challenge iv directly tested for protection against sepsis. Immunization inl
In the present studies, we observed that even though immunization inl used õ1/6 the amount of PspA used in the subcutaneous with PspA from strain R36A protected BALB/c mice against
02-21-97 18:06:43 jinfa UC: J Infect pneumococcal type 6B PS conjugated to 6B-TT in the presence * SE factor is no. by which no. must be multiplied or divided to obtain of CTB. Mice immunized inl three times with 1.5 mg of conjuupper or lower SE limits.
gate produced readily detectable levels of antibody to 6B PS (geometric mean Å 120 ng/mL; SE factor Å 3.4) in sera but barely detectable levels in saliva (geometric mean Å 2.8 ng/ immunizations [32] and induced significantly less serum antibody to PspA than did subcutaneous immunization (table 3), mL; SE factor Å 2.0). Serum antibodies were almost exclusively IgG, but the only salivary antibodies detected were IgA. it still induced enough immunity to significantly delay the time of death after challenge ip ( figure 1D ).
Mice immunized with three doses of 0.3 mg of conjugate generated unmeasurable levels of serum or saliva immunoglobulins Protection against nasopharyngeal carriage by immunization inl with PspA. With the fatal challenge (inl, iv, int, or to 6B PS. The highest levels of carriage were in the control mice given CTB only. Mice immunized with the highest dose ip) models described above, sepsis invariably precedes death. Thus, although mucosal immunity may contribute to protection of 6B-TT had the fewest pneumococci in the nasopharynx (figure 2). The numbers of pneumococci recovered from the against death following inoculation inl and int, protection against death may have been due primarily, if not exclusively, nasopharynx of mice immunized with 6B-TT were significantly lower (P Å .03) than those from control mice. to protection against sepsis. To test whether immunity to PspA can act at the nasopharyngeal mucosa, we used a mouse nasopharyngeal carriage model in which colonization occurs in the Discussion absence of bacteremia and sepsis. Immunization inl with PspA from the capsular type 6B strain L82016 (plus CTB adjuvant)
We observed that immunization inl of mice with PspA was efficacious against otherwise fatal infection when challenged prevented nasopharyngeal colonization with strain L82016; neither PspA nor CTB alone elicited protection (table 4) . Imwith pneumococci int or inl. For challenge int, protection lasted §5 months after immunization. Protection against fatal infecmunity to carriage was still detectable 144 days after boosting (table 5) . This 5-month rest eliminated any concern that protection could have resulted from mucosal immunity, systemic immunity, or both. Systemic immunity to PspA can protect tion against carriage required concomitant CTB-dependent inflammation. Tables 1 and 2 show clearly that the only mice against pneumococcal sepsis [20, 32] . From the present studies, immunization inl with PspA resulted in protective immunity in making anti-PspA responses after immunization inl were those immunized with both PspA and CTB. The requirement for the systemic (protection from challenge iv and ip) and mucosal (protection from carriage) compartments. It is thus likely that mucosal immunity in the protection against carriage was demonstrated by inl challenge of the mice parenterally immunized both mucosal and systemic immunity may have contributed to protection against fatal challenge inl and int. with PspA and colonization factor antigen. Although high levels of serum antibody to PspA were elicited, parenteral immuniTo study immunity at the mucosal surface, we used a model in which carriage could be observed in the absence of sepsis. zation did not elicit mucosal antibody and did not protect against carriage (table 4) .
It should be noted that the ability of pneumococci to cause sepsis versus carriage only after challenge inl of mice is a Cross-protection against carriage by immunization inl with PspA. In the experiment shown in table 4, the immunizing function of both the mouse strain and the strain of pneumococci. In these studies fatal infections following inl inoculation PspA was isolated from the same strain of pneumococcus used / 9d21$$ap14 02-21-97 18:06:43 jinfa UC: J Infect were observed only when A66 pneumococci were used to inocinl and the subcutaneous/ip immunization routes elicited systemic antibody responses, but only immunization inl elicited ulate the hypersusceptible CBA/N mice. Most strains of pneudetectable antibody in secretions. Although it seems likely mococci, however, can cause carriage in mice without accomthat the large amount of IgA antibody to PspA observed in panying sepsis (unpublished data). The absence of sepsis in the secretions plays a role in protection at mucosal sites, the carriage model was critical to our ability to determine that these data do not rule out the possibility that the much protection could act at the mucosal surface. Since mice carrying smaller (largely undetectable) levels of IgG in the secretions the pneumococci in the nasal tissues were not septic, it was or some type of cell-mediated response may contribute to clear that the pneumococci found in the nasopharynx were the resistance observed here. present because they had colonized and not just contaminated Our demonstration that immunization inl with 6B-TT con-(a function of generalized sepsis).
jugate can reduce carriage of pneumococci indicates that imThe protection against carriage appeared to result from munity to antigens other than PspA can also protect against local rather than systemic immunity. For example, both the carriage. CPS, PspA, and IgA protease show the highest degree of serologic variation of any pneumococcal antigens [12, 21, 41] . Since the human reservoir of pneumococci is thought to be maintained primarily by nasopharyngeal carriage, it might be expected that the evolutionary selection that has driven serologic variation in CPS, PspA, and IgA protease acts at the level of carriage, rather than at systemic infection. Mouse IgA is not cleaved by pneumococcal IgA1 protease, and we did not attempt to assess the protectioneliciting role of this potential virulence factor in mice. In the case of immunity to PspA and capsule, however, protection against carriage was observed. The ability of PspA and the 6B-TT conjugate to elicit protection against nasopharyngeal carriage in mice raises the possibility that mucosal immunity to these antigens might confer protection against carriage in humans. The observation that immunization with PspA can cross-protect against carriage strains bearing different PspAs enhances the prospects for the use of PspA as a mucosal vaccine. Moreover, in tests of the cross-protection elicited by individual PspA immunogens, the carriage model may have one advantage over the systemic infection model. Strains of many capsular types, including 
